-
The first continuous manufacturing guide in China is coming, and the pharmaceutical industry will usher in major changes!
Time of Update: 2022-10-13
In order to encourage innovation and pharmaceutical modernization, to help the implementation of the ICH Q13 guidelines in China, but also to guide enterprises in research and development, unified re
-
Expand the scope of "inter-provincial communication" of government services to further improve service efficiency
Time of Update: 2022-10-13
The people's governments of all provinces, autonomous regions and municipalities directly under the Central Government, and the ministries and commissions and agencies directly under the State Counci
-
Why has Hainan's gradual abolition of general outpatient clinics in tertiary public hospitals caused widespread concern?
Time of Update: 2022-10-13
This news stems from the "Implementation Plan for Promoting the High-quality Development of Public Hospitals in Hainan Province" issued by the General Office of the Hainan Provincial Government not long ago, which proposes to strictly control the number and scale of tertiary public hospitals in the next three to five years, and gradually cancel the general outpatient clinics in these hospitals.
-
Sailing Pharmaceutical: Bone health public welfare + sports, multi-dimensional implementation of corporate mission
Time of Update: 2022-10-13
Join hands with Yunnan Provincial GamesLove with athletes and the publicExercise and bone health support each other, and the importance of sports to improve the bone health of middle-aged and elderly people is self-evident.
-
The development of the pharmacy sector continues to improve, and the revenue growth of industry leaders in the second half of the year can be expected
Time of Update: 2022-10-13
The data shows that due to the high base of the epidemic in 2020, short-term financial and other factors, the growth rate of the pharmacy industry continued to decline in the second half of 2021.
-
The Chinese medicine tablet industry maintained a high-speed growth trend, achieving a profit of nearly 7.9 billion yuan in the first half of the year
Time of Update: 2022-10-13
2 billion yuan, continuing to maintain a substantial growth trend; In the second quarter, the profit of the Chinese medicine tablet industry increased by 10.
2 billion yuan, continuing to maintain a substantial growth trend; In the second quarter, the profit of the Chinese medicine tablet industry increased by 10.
-
Heparin TOP5 listed pharmaceutical companies Fawei, half a year a total of nearly 10 billion!
Time of Update: 2022-10-13
According to Hepalink's semi-annual report, in the first half of 2022, the company's global sales of enoxaparin sodium preparations exceeded 114 million pieces, and the year-on-year sales volume in domestic sales terminals and overseas markets that have been opened up has achieved double-digit growth, of which the year-on-year sales growth in the US market has reached 184.
-
Two vice presidents of pharmaceutical companies resigned in one day, both less than a year in office!
Time of Update: 2022-10-13
On the same day, Meinian Health announced that Ms. Lin Qing applied to resign as vice president and secretary of the board of directors of the company for personal reasons, and no longer held any position in the company after resignation.
-
The State Food and Drug Administration on the Publication of the Catalogue of Generic Drug Reference Preparations (60th Batch)
Time of Update: 2022-10-13
After the review and confirmation of the Expert Committee on the Consistency Evaluation of Generic Drugs and Efficacy of the State Drug Administration, the Catalogue of Generic Reference Preparations
-
Online medical insurance payment landed in these cities, pharmacy operation O2O needs to do a good job of 4 points!
Time of Update: 2022-10-13
MiIntranet predicts that the scale of retail pharmacy terminals will rise to 1,150 billion yuan in 2029, and the share of the six major markets of the three major terminals will increase significantly, of which the overall market size of physical pharmacies will reach 750 billion yuan, and its scale growth is bound to drive the rise of O2O scale.
-
Rising raw material prices, how should pharmaceutical machinery companies respond?
Time of Update: 2022-10-13
Therefore, in order to cope with the challenge of rising raw material prices, pharmaceutical machinery enterprises should strengthen their operation and management, change from extensive to lean management mode, reduce costs, improve quality, speed up processes and improve capital investment, so as to achieve greater value.
-
The seventh batch of national procurement is about to land, and many provinces have issued documents to start preliminary work
Time of Update: 2022-10-13
On August 9, the Procurement Center of the Inner Mongolia Autonomous Region issued the Notice on Preparing for the Implementation of the Results of the Seventh Batch of National Centralized Procurement Drugs.
-
The use of digitalization to promote innovative marketing of medicine has become the focus of attention in the industry
Time of Update: 2022-10-13
js?cdnversion='+~(-new Date()/36e5)]; With the implementation of documents such as consistency evaluation, "two-vote system", VAT reform, and the normalization of "4+7" procurement with quantity, traditional pharmaceutical marketing is gradually difficult.
-
Announcement of the State Food and Drug Administration on the revision of the instructions for cefazolin injection
Time of Update: 2022-10-13
The marketing authorization holders of the above-mentioned drugs shall report to the Drug Evaluation Center of the State Drug Administration or the provincial drug supervision and administration department for the record before December 30, 2022 in accordance with the relevant provisions of the Measures for the Administration of Drug Registration and other relevant provisions and in accordance with the requirements for the revision of the instructions of cefazolin injections (see annex).
-
In 2022, the size of this drug market will reach 20 billion yuan!
Time of Update: 2022-10-13
In addition, a large number of domestic drugs are in the clinical trial or application for listing stage, among which the class 1 chemical new drug Ansulfaxin hydrochloride extended-release tablets independently developed by Luye Pharmaceutical Group have submitted a marketing application on June 11, 2021, which is suitable for major depressive disorder.
-
Xinjiang: The entire Xinjiang drug inventory can basically ensure the market demand for 30 days
Time of Update: 2022-10-13
On the evening of the 7th, Xinjiang held a press conference on epidemic prevention and control. Tian Chunhai, deputy director of the Xinjiang Drug Administration, said in response to a reporter's que
-
With the wave of financing for pharmaceutical companies, these areas are attracting much attention
Time of Update: 2022-10-13
On Oct. 7, oncology company Nested Therapeutics announced the completion of a $90 million Series A funding round, which will advance Nested's total funding to $125 million to help develop its next generation of cancer precision medicine drugs.
-
Carry out the pilot work of high-quality development of public hospitals in Shanghai
Time of Update: 2022-10-13
Relevant members of the Municipal Leading Group for Deepening Medical Reform, medical reform offices in various districts, and relevant medical institutions: In order to implement the spirit of the O
-
Notice on the Public Solicitation of Opinions on the Technical Guidelines for the Preparation and Research of Drugs for Clinical Trial Use of New Chinese Medicines (Draft for Solicitation of Comments).
Time of Update: 2022-10-12
Release date: 20220927 In order to accelerate the establishment and improvement of a technical evaluation system that meets the characteristics of traditional Chinese medicines and promote the research and development and innovation of new drugs based on traditional Chinese medicines in China, the Drug Review Center has drafted the "Technical Guidelines for the Preparation and Research of Drugs for Clinical Trial of New Drugs in Traditional Chinese Medicines".
-
In October, a batch of drugs were evaluated, and some varieties won the first home!
Time of Update: 2022-10-12
Enhua Pharmaceutical announced at noon on October 10 that the company's flumazenil injection recently passed the consistency evaluation of generic drug quality and efficacy.
Enhua Pharmaceutical announced at noon on October 10 that the company's flumazenil injection recently passed the consistency evaluation of generic drug quality and efficacy.
